Praxis Precision Medicines Inc logo

PRAX

Praxis Precision Medicines Inc

$3.8

Earnings Summary

Revenue
$0Mn
Net Profits
$-68.72Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Praxis Precision Medicines Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Praxis Precision Medicines Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Praxis Precision Medicines Inc’s net profit fell -151.04% since last year same period to $-68.72Mn in the Q1 2022. On a quarterly growth basis, Praxis Precision Medicines Inc has generated 58.87% jump in its net profits since last 3-months.

Net Profit Margins:

Praxis Precision Medicines Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Praxis Precision Medicines Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Praxis Precision Medicines Inc post its latest quarter earnings

EPS Estimate Current Quarter
-1.3
EPS Estimate Current Year
-1.3

Highlights

EPS Estimate Current Quarter:

Praxis Precision Medicines Inc’s earning per share (EPS) estimates for the current quarter stand at -1.3 - a 0% jump from last quarter’s estimates.

EPS Estimate Current Year:

Praxis Precision Medicines Inc’s earning per share (EPS) estimates for the current year stand at -1.3.

Key Ratios

Key ratios of the Praxis Precision Medicines Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-1.51
Return on Assets (ROA)
-0.54
Return on Equity (ROE)
-0.98
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Praxis Precision Medicines Inc’s earning per share (EPS) fell -112.68% since last year same period to -1.51 in the Q1 2022. This indicates that the Praxis Precision Medicines Inc has generated -112.68% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Praxis Precision Medicines Inc’s return on assets (ROA) stands at -0.54.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Praxis Precision Medicines Inc’s return on equity (ROE) stands at -0.98.

Dividend Per Share (DPS):

Praxis Precision Medicines Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-1.3
-1.51
-16.15%

Company Information

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio, including multiple disclosed programs across CNS disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates.

Organisation
Praxis Precision Medicines Inc
Employees
2.02K
Industry
Health Technology